Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
JCO Precision Oncology
|
January 20, 2022
Targeted Therapy in BRAF p.K601E-Driven NSCLC: Case Report and Literature Review
Felix C Saalfeld, Carina Wenzel, Daniela E Aust, et al.
Translational Lung Cancer Research
|
April 23, 2021
The clinical benefit of molecular re-assessments in management of progressive lung cancer
Carina Wenzel, Sylvia Herold, Felix C Saalfeld, et al.
Cancer Discovery
|
September 4, 2025
Histologic Transformation in Cancer: The Path for Clinical Translation
Ioannis Vathiotis, Avisek Banerjee, Utsav Sen, et al.
Acta Neuropathologica Communications
|
January 7, 2021
Sporadic multiple meningiomas harbor distinct driver mutations
Tareq A Juratli, Insa Prilop, Felix C Saalfeld, et al.
Therapeutic Advances in Medical Oncology
|
June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
Jan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
Frontiers in Oncology
|
October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
Friederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Clinical Lung Cancer
|
June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
The Journal of Clinical Investigation
|
July 20, 2018
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Bärbel Edelmann, Nibedita Gupta, Tina M Schnoeder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
Felix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
Petros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
JCO Precision Oncology
|
January 20, 2022
Targeted Therapy in BRAF p.K601E-Driven NSCLC: Case Report and Literature Review
Felix C Saalfeld, Carina Wenzel, Daniela E Aust, et al.
Translational Lung Cancer Research
|
April 23, 2021
The clinical benefit of molecular re-assessments in management of progressive lung cancer
Carina Wenzel, Sylvia Herold, Felix C Saalfeld, et al.
Cancer Discovery
|
September 4, 2025
Histologic Transformation in Cancer: The Path for Clinical Translation
Ioannis Vathiotis, Avisek Banerjee, Utsav Sen, et al.
Acta Neuropathologica Communications
|
January 7, 2021
Sporadic multiple meningiomas harbor distinct driver mutations
Tareq A Juratli, Insa Prilop, Felix C Saalfeld, et al.
Therapeutic Advances in Medical Oncology
|
June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
Jan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
Frontiers in Oncology
|
October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
Friederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Clinical Lung Cancer
|
June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
The Journal of Clinical Investigation
|
July 20, 2018
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Bärbel Edelmann, Nibedita Gupta, Tina M Schnoeder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
Felix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
Petros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Page
of 1